(R)-NX-2127, identified by its CAS number 3024312-52-2, is a chemical compound that belongs to a class of substances known for their potential therapeutic applications, particularly in the field of neuroscience. As a chiral molecule, it exhibits stereoisomerism, which can significantly influence its biological activity and pharmacokinetics. The compound is typically characterized by its specific molecular structure, which includes functional groups that may interact with biological targets, such as receptors or enzymes. Its solubility, stability, and reactivity can vary based on environmental conditions, such as pH and temperature. Research into (R)-NX-2127 has focused on its efficacy and safety profile, with studies often examining its effects on neurotransmitter systems. As with many investigational compounds, detailed information regarding its pharmacodynamics, pharmacokinetics, and potential side effects is crucial for understanding its therapeutic potential. Further studies and clinical trials are essential to fully elucidate its characteristics and applications in medicine.

(R)-NX-2127

3024312-52-2: (R)-NX-2127, identified by its CAS number 3024312-52-2, is a chemical compound that belongs to a class of substances known for their potential therapeutic applications, particularly in the field of neuroscience. As a chiral molecule, it exhibits stereoisomerism, which can significantly influence its biological activity and pharmacokinetics. The compound is typically characterized by its specific molecular structure, which includes functional groups that may interact with biological targets, such as receptors or enzymes. Its solubility, stability, and reactivity can vary based on environmental conditions, such as pH and temperature. Research into (R)-NX-2127 has focused on its efficacy and safety profile, with studies often examining its effects on neurotransmitter systems. As with many investigational compounds, detailed information regarding its pharmacodynamics, pharmacokinetics, and potential side effects is crucial for understanding its therapeutic potential. Further studies and clinical trials are essential to fully elucidate its characteristics and applications in medicine.

3-((4-(1-(((3R)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)phenyl)amino)-5-(piperidin-1-yl)pyrazine-2-carboxamide

CAS 3024312-52-2

(R)-NX-2127

3-((4-(1-(((3R)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)phenyl)amino)-5-(piperidin-1-yl)pyrazine-2-carboxamide

Ref: 54-OR1067129

Zelebrudomide (NX 2127)

Ref: 4Z-Z-036001